The Lancet Regional Health – Europe publishes ‘real-world evidence’ from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma
COPENHAGEN, Denmark, Dec. 1, 2021 /PRNewswire/ — ALK (ALKB: DC) (OMX: ALK B) (OMX: AKABY) (OMX: AKBLF) today announced that results from the REACT study, a large retrospective real-world study comprising more...